Aspiriant LLC Lowers Position in The Clorox Company (NYSE:CLX)

Aspiriant LLC decreased its holdings in shares of The Clorox Company (NYSE:CLX) by 12.2% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,604 shares of the company’s stock after selling 222 shares during the period. Aspiriant LLC’s holdings in Clorox were worth $246,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Fortitude Family Office LLC purchased a new stake in shares of Clorox in the 4th quarter worth $29,000. Northwest Financial Advisors bought a new position in Clorox in the 4th quarter worth $29,000. Core Wealth Advisors Inc. bought a new position in Clorox in the 4th quarter worth $29,000. First United Bank & Trust bought a new position in Clorox in the 4th quarter worth $31,000. Finally, GoalVest Advisory LLC bought a new position in Clorox in the 1st quarter worth $31,000. Institutional investors own 78.53% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently weighed in on CLX. Barclays dropped their target price on shares of Clorox from $136.00 to $132.00 and set an “underweight” rating for the company in a report on Thursday, May 2nd. BNP Paribas started coverage on shares of Clorox in a report on Monday. They set an “underperform” rating and a $130.00 price objective for the company. DA Davidson reissued a “neutral” rating and set a $162.00 price objective on shares of Clorox in a report on Wednesday, April 17th. Citigroup decreased their target price on shares of Clorox from $155.00 to $150.00 and set a “neutral” rating on the stock in a research report on Wednesday, May 1st. Finally, UBS Group decreased their target price on shares of Clorox from $164.00 to $159.00 and set a “neutral” rating on the stock in a research report on Wednesday, May 1st. Five research analysts have rated the stock with a sell rating and fourteen have assigned a hold rating to the company’s stock. Based on data from MarketBeat, Clorox has a consensus rating of “Hold” and an average target price of $145.33.

Clorox Price Performance

NYSE CLX opened at $135.29 on Thursday. The company has a debt-to-equity ratio of 9.73, a quick ratio of 0.53 and a current ratio of 0.90. The firm’s 50 day moving average price is $137.37 and its 200-day moving average price is $143.92. The Clorox Company has a 52-week low of $114.68 and a 52-week high of $169.14. The company has a market cap of $16.80 billion, a PE ratio of 70.10, a P/E/G ratio of 2.15 and a beta of 0.39.

Clorox (NYSE:CLX) last announced its earnings results on Tuesday, April 30th. The company reported $1.71 earnings per share for the quarter, beating the consensus estimate of $1.33 by $0.38. The company had revenue of $1.81 billion during the quarter, compared to the consensus estimate of $1.87 billion. Clorox had a net margin of 3.33% and a return on equity of 302.49%. Clorox’s revenue was down 5.3% compared to the same quarter last year. During the same period last year, the firm earned $1.51 earnings per share. Sell-side analysts forecast that The Clorox Company will post 5.91 EPS for the current fiscal year.

Clorox Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.